ELISA/assay

Rabbit luteinizing hormone, LH ELISA Kit

MBS912114

48-Strip-Wells

565 USD

ELISA Kit

Rabbit luteinizing hormone, LH ELISA Kit

luteinizing hormone (LH) ELISA kit

Rabbit luteinizing hormone (LH) ELISA kit; luteinizing hormone (LH) ELISA kit

luteinizing hormone receptor; Lutropin-choriogonadotropic hormone receptor; lutropin-choriogonadotropic hormone receptor; hypergonadotropic hypogonadism; lutropin/choriogonadotropin receptor; luteinizing hormone/choriogonadotropin receptor; Luteinizing hormone receptor; LHR; LSH-R

LH

LHCGR; LHCGR; HHG; LHR; LCGR; LGR2; ULG5; LHRHR; LSH-R; LH/CGR; LH/CG-R; LCGR; LGR2; LHRHR; LH/CG-R; LHR; LSH-R

LSHR_HUMAN

Rabbit

699

This assay has high sensitivity and excellent specificity for detection of rabbit LH. No significant cross-reactivity or interference between rabbit LH and analogues was observed.

Unopened test kits should be stored at 2 to 8 degree C upon receipt. Please refer to pdf manual for further storage instructions.

Samples: Serum, plasma, tissue homogenates. Assay Type: Sandwich. Detection Range: 1.56 mIU/ml -100mIU/ml. Sensitivity: The minimum detectable dose of rabbit LH is typically less than 0.39 mlU/ml. The sensitivity of this assay, or Lower Limit of Detection (LLD) was defined as the lowest protein concentration that could be differentiated from zero. It was determined the mean O.D value of 20 replicates of the zero standard added by their three standard deviations.

Intra-assay Precision: Intra-assay Precision (Precision within an assay): CV%<8%. Three samples of known concentration were tested twenty times on one plate to assess. Inter-assay Precision: Inter-assay Precision (Precision between assays): CV%<10%. Three samples of known concentration were tested in twenty assays to assess.

Principle of the Assay: This assay employs the quantitative sandwich enzyme immunoassay technique. Antibody specific for LH has been pre-coated onto a microplate. Standards and samples are pipetted into the wells and any LH present is bound by the immobilized antibody. After removing any unbound substances, a biotin-conjugated antibody specific for LH is added to the wells. After washing, avidin conjugated Horseradish Peroxidase (HRP) is added to the wells. Following a wash to remove any unbound avidin-enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of LH bound in the initial step. The color development is stopped and the intensity of the color is measured.

7704943

AAB19917.2

P22888

71,615 Da

Arf6 Signaling Events Pathway (138034); Calcium Signaling Pathway (83050); Calcium Signaling Pathway (459); Class A/1 (Rhodopsin-like Receptors) Pathway (106357); G Alpha (s) Signalling Events Pathway (119549); GPCR Downstream Signaling Pathway (119548); GPCR Ligand Binding Pathway (161020); GPCRs, Class A Rhodopsin-like Pathway (198886); Hormone Ligand-binding Receptors Pathway (106369); Neuroactive Ligand-receptor Interaction Pathway (83053)

This gene encodes the receptor for both luteinizing hormone and choriogonadotropin. This receptor belongs to the G-protein coupled receptor 1 family, and its activity is mediated by G proteins which activate adenylate cyclase. Mutations in this gene result in disorders of male secondary sexual character development, including familial male precocious puberty, also known as testotoxicosis, hypogonadotropic hypogonadism, Leydig cell adenoma with precocious puberty, and male pseudohermaphtoditism with Leydig cell hypoplasia. [provided by RefSeq, Jul 2008]

LHR: Receptor for lutropin-choriogonadotropic hormone. The activity of this receptor is mediated by G proteins which activate adenylate cyclase. Defects in LHCGR are a cause of familial male precocious puberty (FMPP); also known as testotoxicosis. In FMPP the receptor is constitutively activated. Defects in LHCGR are the cause of luteinizing hormone resistance (LHR); also known as Leydig cell hypoplasia in males. LHR is an autosomal recessive disorder characterized by unresponsiveness to luteinizing hormone, defective sexual development in males, and defective follicular development and ovulation, amenorrhea and infertility in females. Two forms of the disorder have been defined in males. Type 1 is a severe form characterized by complete 46,XY male pseudohermaphroditism, low testosterone and high luteinizing hormone levels, total lack of responsiveness to luteinizing and chorionic gonadotropin hormones, lack of breast development, and absent development of secondary male sex characteristics. Type 2, a milder form, displays a broader range of phenotypic expression ranging from micropenis to severe hypospadias. Belongs to the G-protein coupled receptor 1 family. FSH/LSH/TSH subfamily. 2 isoforms of the human protein are produced by alternative splicing. Protein type: GPCR, family 1; Membrane protein, multi-pass; Membrane protein, integral; Receptor, GPCR. Chromosomal Location of Human Ortholog: 2p21. Cellular Component: integral to plasma membrane; plasma membrane; endosome. Molecular Function: lutropin-choriogonadotropic hormone receptor activity. Biological Process: G-protein coupled receptor protein signaling pathway; G-protein signaling, coupled to cyclic nucleotide second messenger; adenylate cyclase activation; male gonad development; male genitalia development; G-protein signaling, coupled to IP3 second messenger (phospholipase C activating); positive regulation of inositol trisphosphate biosynthetic process; luteinizing hormone signaling pathway; cognition. Disease: Precocious Puberty, Male-limited; Leydig Cell Hypoplasia, Type I

48-Strip-Wells

565 USD

96-Strip-Wells

810

5x96-Strip-Wells

2750

10x96-Strip-Wells

5150